相关实验视频
Updated: Jun 13, 2025

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.6K
在袖子胃切除术后发生性低血糖症
Jinwen He1,2, Liza Phillips1,2, Janelle Nisbet1
1Mater Health, Brisbane, Australia.
Clinical endocrinology
|March 25, 2025
概括
在袖子胃切除术后,确定了两例非胰岛素介导的性低血糖症. 类似葡萄糖-1受体激活剂疗法有效地管理了这些罕见的腹术后并发症.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 胃肠病学 胃肠病学
背景情况:
- 腹腔外科手术后低血糖症通常与高胰岛素血症有关,但潜在的机制需要进一步阐明.
- 袖子胃切除术是一种常见的减肥手术,与各种代谢变化有关.
研究的目的:
- 在袖子胃切除术后呈现两例非胰岛素介导的性低血糖症.
- 探索这种罕见并发症的潜在机制和管理策略.
- 调查类似葡萄糖-1受体激动剂在治疗这种病例中的疗效.
主要方法:
- 病例报告:两名患者在袖子胃切除术后出现症状性低血糖症.
- 生物化学分析包括胰岛素,C-,β-基酸盐,皮质醇和IGF1水平.
- 评估潜在的潜在原因,如代谢的先天性错误.
- 评估饮食管理和药理干预与塞马格卢提德.
主要成果:
- 两位患者在长时间禁食 (40小时和65小时) 后出现了性低血糖症.
- 实验室发现显示胰岛素低,C低,β-基酸盐升高.
- 标准的饮食管理是不够的; 塞马格卢提德治疗导致低血糖事件的解决或显著减少.
结论:
- 非胰岛素介导的性低血糖是袖子胃切除术的潜在并发症.
- 机制可能涉及改变的葡萄糖生成或暴露的代谢障碍.
- 塞马格卢提德显示承诺作为这种情况的有效治疗方法.
相关概念视频
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Insulin: Dosing Regimen and Adverse Effects
157
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Pathophysiology of Diabetes
906
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
906
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147

